Literature DB >> 4023730

Bone changes from prostaglandin therapy.

A K Poznanski, S K Fernbach, T E Berry.   

Abstract

Prostaglandin E therapy in infants causes periosteal elevation. Although the changes usually take 30-40 days to become visible, we have seen them as early as nine days. In 15 infants who had prostaglandin E therapy for over six days, three developed periosteal elevation. Three other cases are described in greater detail, with long-term follow-up in two in which the bone remodeled to normal. Gallium scan in one showed increased uptake in areas involved. The periosteal cloaking may mimic Caffey disease but the pattern of involvement is different, since the mandible, which is commonly affected in Caffey disease, is rarely involved in prostaglandin E therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4023730     DOI: 10.1007/bf00361189

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  12 in total

1.  Prostaglandin synthesis by osteoid osteoma.

Authors:  J T Makley; M J Dunn
Journal:  Lancet       Date:  1982-07-03       Impact factor: 79.321

2.  Prostaglandin-induced periostitis: a complication of long-term PGE1 infusion in an infant with congenital heart disease.

Authors:  R E Ringel; J I Brenner; P J Haney; J E Burns; A L Moulton; M A Berman
Journal:  Radiology       Date:  1982-03       Impact factor: 11.105

Review 3.  Drug and hormone effects on calcium release from bone.

Authors:  T J Martin
Journal:  Pharmacol Ther       Date:  1983       Impact factor: 12.310

4.  Periosteal changes secondary to prostaglandin administration.

Authors:  R E Ringel; P J Haney; J I Brenner; T J Mancuso; G S Roberts; A L Moulton; M A Berman
Journal:  J Pediatr       Date:  1983-08       Impact factor: 4.406

5.  [Prostaglandin-induced periostitis].

Authors:  T Nakagawa; S Hamada; T Nishiki; I Yamamoto; K Tachi; H Takahashi
Journal:  Rinsho Hoshasen       Date:  1983-06

6.  Prostaglandin synthetase inhibitor in Caffey disease.

Authors:  E Heyman; J Laver; S Beer
Journal:  J Pediatr       Date:  1982-08       Impact factor: 4.406

7.  Cortical hyperostosis following long-term administration of prostaglandin E1 in infants with cyanotic congenital heart disease.

Authors:  K Ueda; A Saito; H Nakano; M Aoshima; M Yokota; R Muraoka; T Iwaya
Journal:  J Pediatr       Date:  1980-11       Impact factor: 4.406

8.  Long-term low-dose prostaglandin E1 administration.

Authors:  K Sone; M Tashiro; T Fujinaga; T Tomomasa; K Tokuyama; T Kuroume
Journal:  J Pediatr       Date:  1980-11       Impact factor: 4.406

9.  Stimulation of bone formation by prostaglandin E2.

Authors:  Y S Chyun; L G Raisz
Journal:  Prostaglandins       Date:  1984-01

10.  Prostaglandins are necessary for osteoclast-activating factor production by activated peripheral blood leukocytes.

Authors:  T Yoneda; G R Mundy
Journal:  J Exp Med       Date:  1979-01-01       Impact factor: 14.307

View more
  5 in total

1.  Plain film and CT observations in prostaglandin-induced bone changes.

Authors:  M A Matzinger; V A Briggs; H J Dunlap; K Udjus; D J Martin; P McDonald
Journal:  Pediatr Radiol       Date:  1992

2.  Chronic recurrent multifocal osteomyelitis associated with chronic inflammatory bowel disease in children.

Authors:  A Bousvaros; M Marcon; W Treem; P Waters; R Issenman; R Couper; R Burnell; A Rosenberg; E Rabinovich; B S Kirschner
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

3.  Cortical hyperostosis simulating osteomyelitis after short-term prostaglandin E1 infusion.

Authors:  A K Kalloghlian; H H Frayha; M M deMoor
Journal:  Eur J Pediatr       Date:  1996-03       Impact factor: 3.183

4.  Case report 701: Prostaglandin E1 (PGE1) periostitis.

Authors:  R F Rowley; J P Lawson
Journal:  Skeletal Radiol       Date:  1991       Impact factor: 2.199

Review 5.  Lesions of juxtacortical origin (surface lesions of bone).

Authors:  S Kenan; I F Abdelwahab; M J Klein; G Hermann; M M Lewis
Journal:  Skeletal Radiol       Date:  1993       Impact factor: 2.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.